Valneva Announces Phase 2 Trials Of Lyme Disease Vaccine Candidate, VLA15 Have Been Published In 'The Lancet Infectious Diseases'
Portfolio Pulse from Benzinga Newsdesk
Valneva SE announced that the results of two Phase 2 clinical trials for its Lyme disease vaccine candidate, VLA15, have been published in 'The Lancet Infectious Diseases'. These trials, along with a third Phase 2 trial in pediatric participants, support the design of the current pivotal Phase 3 trial, VALOR.
June 03, 2024 | 3:46 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Valneva SE has published Phase 2 trial results for its Lyme disease vaccine candidate, VLA15, in 'The Lancet Infectious Diseases'. This supports the ongoing Phase 3 trial, VALOR.
The publication of Phase 2 trial results in a reputable journal like 'The Lancet Infectious Diseases' is a significant milestone. It validates the progress of VLA15 and supports the ongoing Phase 3 trial, which could lead to regulatory approval and commercialization. This positive development is likely to boost investor confidence and positively impact the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100